Clinical characteristics and drug-drug interactions in hu...

연구 요약

Clinical characteristics and drug-drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study.

The oncologist 학술지에 발표된 이 연구는 Pisegna S, Scagnoli S, Gentile G 외 연구팀이 수행하였습니다.

핵심 내용

BACKGROUND: Trastuzumab deruxtecan (T-DXd) reshaped clinical practice in human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC). The impact of clinical characteristics and drug-drug interactions (DDIs) on outcomes in patients receiving T-DXd is still under investigation. METHODS: We retrospectively analyzed data of patients from the Italian DE-REAL study. Clinical features including age, body mass index (BMI), toxicity and DDIs were assessed and correlated with clinical outcomes. The Drug-PIN software was used to evaluate DDIs. RESULTS: Among 143 patients, age did not significantly affect progression-free survival (PFS) but influenced overall survival (OS), with younger patients (<65 years) showing better outcomes (median overall survival [mOS]: 12 vs. 10 months, P = 0.02). Patients with BMI >25 demonstrated significantly longer PFS (11 vs. 9 months, P = 0.04), which was confirmed as independent predictor of better PFS at multivariate analysis (P ≤0.05), but experienced higher toxicity rates, particularly nausea (P = 0.019). Drug-PIN classification showed no impact on survival outcomes, although patients with high-risk DDIs experienced more nausea and asthenia compared to those with low-risk interactions (P = 0.0018 and P = 0.003, respectively). CONCLUSION: T-DXd efficacy appears consistent across different age groups, although elderly patients showed reduced OS. Higher BMI was associated with improved PFS but increased toxicity.

일반인을 위한 해석

이 연구는 약물 또는 영양제의 안전한 사용에 관한 과학적 근거를 제공할 수 있습니다. 다만, 개별 연구 결과만으로 일반화하기는 어려우며, 추가적인 연구가 필요할 수 있습니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41587947)